{"filing":{"accession_number":"0001193125-26-266717","cik":"0001488039","ticker":"ATOS","company_name":"ATOSSA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"atos-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm"},"events":[{"id":5336,"run_id":4674,"accession_number":"0001193125-26-266717","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.","company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6094,"accession_number":"0001193125-26-266717","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:01:10.515864+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6094,"accession_number":"0001193125-26-266717","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:01:10.515864+00:00","company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","filing_date":"2026-06-11"}]}